Genmab A/s Stock Earnings Reports

Key investor takeaways from Genmab Q1 2026 call: 1) Strong financial performance: total revenue +25% YoY; proprietary product sales $176M (+43% YoY), with EPKINLY $137M (+52% YoY) and Tivdak $39M (+18% YoY). Operating profit grew ~23%. 2) 2026 is a catalyst-rich year: multiple near-term readouts expected (notably Rina‑S and petosemtamab/EPCORE programs). Management reiterated timing guidance for petosemtamab and EPKINLY and highlighted several pivotal milestones. 3) Rina‑S acceleration: two new Phase III trials planned to start imminently (including a frontline endometrial trial and a chemo‑replacement trial in platinum‑sensitive ovarian cancer); the RAINFOL‑02 Phase III in second‑line+ platinum‑resistant ovarian cancer has completed enrollment, bringing pivotal data into 2026 and supporting potential earlier global filings. 4) Petosemtamab program: some frontline trial size increases to improve probability of success, but management says this will not change the expected readout timing (one or more petosemtamab readouts expected this year). 5) EPKINLY commercial momentum and label change: strong uptake across settings (academic and community), label revision in the U.S. removed mandatory 24‑hour hospitalization recommendation for first full dose in third‑line+ DLBCL, expected to broaden outpatient/community use; management is focused on earlier‑line expansion and combinations. 6) Guidance and capital allocation: reaffirmed 2026 guidance (midpoint ~14% total revenue growth), planned operating expenses ~$2.7–$2.9B to fund late‑stage development and launches while maintaining substantial profitability; tax rate noted (~28.9%) may be variable during Merus integration; target to deleverage to gross leverage <3x by end‑2027. 7) Integration and pipeline focus: Merus integration underway (petosemtamab value capture), disciplined investments in late‑stage assets (Rina‑S, petosemtamab, EPKINLY) and launch readiness emphasized. Overall, the company is growing revenue, maintaining profitability while funding an expanded late‑stage pipeline and expecting several near‑term regulatory/commercial catalysts in 2026–2027.